Diversified Specialty Institute Holdings, Inc.

Green Shield expands pharmacy focus with acquisitions of NKS Health and The Health Depot

Retrieved on: 
Wednesday, March 9, 2022
Industry, Multiple sclerosis, Green Shield Canada, GSH, Physician, Rheumatoid arthritis, Digital technology, GSA, Elijah Cummings Lower Drug Costs Now Act, EVP, Health, Heath, Pharmacy, Conditional sentence, Pharmaceutical Services Negotiating Committee, Entrepreneurship, Non-Insured Health Benefits, Diversified Specialty Institute Holdings, Inc., Patient, Telehealth, Pharmacist, Mental health, Stroke, GSC, Technology, Solution, Migraine, Growth, Degenerative disease, Insurance, History, Program, CEO, Healthcare, Hospital, Health insurance, Medicine

In light of the growth trend in digital health, the GSC group of companies is also acquiring The Health Depot , an emerging leader in digital pharmacy with expertise in chronic disease management.

Key Points: 
  • In light of the growth trend in digital health, the GSC group of companies is also acquiring The Health Depot , an emerging leader in digital pharmacy with expertise in chronic disease management.
  • About Green Shield Holdings Inc.
    Part of the Green Shield Canada (GSC) group of companies, Green Shield Holdings Inc. (GSH) is the primary company used to house health services and health & benefits administration subsidiaries.
  • Green Shield Holdings Inc. is itself a wholly-owned subsidiary of the not-for-profit Green Shield Association (GSA).
  • NKS Health is a specialty pharmaceutical services company focused on the handling and service of injectable, infused and biologic medications.

Inkblot Therapy and Green Shield Association Launch Free Room for Her Digital Hub

Retrieved on: 
Tuesday, March 8, 2022
Workforce, Research, Woman, Workplace, Room, Public policy, Risk, Diversified Specialty Institute Holdings, Inc., Social support, Mental health, International Women's Day, Mental, BIPOC, International Women's Health Coalition, Program, Social isolation, Protective factor, Medicine, Rorschach test

Inkblot Also Named a "Best Workplace for Women" by Great Place to Work

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - March 8, 2022) - Today, on International Women's Day, Inkblot Therapy (Inkblot) and the Green Shield Association announce the launch of the new Room for Her digital hub .
  • Funded by the Green Shield Association and delivered by Inkblot, Room for Her was launched on November 9, 2021.
  • The Room for Her digital hub will specifically include the following resources:
    Mental Health educational materials: The hub will focus on enhancing protective factors (e.g.
  • Free counselling support: The hub will be the primary access point for the free Room for Her counselling program.

Clever Leaves to Present at the 34th Annual ROTH Conference

Retrieved on: 
Tuesday, March 8, 2022
NASDAQ, Industry, The Ritz-Carlton Hotel Company, Leaf, Conference, API, Diversified Specialty Institute Holdings, Inc., BOCA, GLOBE, CA, LinkedIn

BOCA RATON, Fla., March 08, 2022 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (Clever Leaves or the Company), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, is scheduled to participate in the 34th Annual ROTH Conference, which is being held on March 13-15, 2022 at the Ritz Carlton in Dana Point, CA.

Key Points: 
  • BOCA RATON, Fla., March 08, 2022 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (Clever Leaves or the Company), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, is scheduled to participate in the 34th Annual ROTH Conference, which is being held on March 13-15, 2022 at the Ritz Carlton in Dana Point, CA.
  • Clever Leaves management is scheduled to present on Tuesday, March 15th at 2:00 p.m. Pacific time.
  • To receive additional information, request an invitation or schedule a one-on-one meeting with Clever Leaves management, please contact your ROTH representative or the Companys investor relations team at [email protected] .
  • For more information, please visit https://cleverleaves.com/en/home/ and follow Clever Leaves on Twitter and LinkedIn.

Clever Leaves Partners With FoliuMed to Import Colombian Cannabis EU-GMP Bulk Extracts Into Germany

Retrieved on: 
Wednesday, March 2, 2022
Patient, Good manufacturing practice, Industry, THC, Fidelio, API, LinkedIn, Certification, German, EU, GMP, CEO, Diversified Specialty Institute Holdings, Inc., CBD, Partnership, Folium, Union, Leaf, GLOBE, NASDAQ, Drug, Pharmaceutical industry

BOCA RATON, Fla., March 02, 2022 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, has signed a one-year international sales agreement with German- Colombian operator FoliuMed Holdings (“FoliuMed”) and its German manufacturing partner, Fidelio Healthcare (“Fidelio”). With access to three of Clever Leaves’ pharmaceutical grade bulk cannabis extracts, Fidelio will be ramping up production using Clever Leaves’ full spectrum THC crude extract, standardized 20% CBD extract, and CBD isolate.

Key Points: 
  • A supply agreement between cannabis operators Clever Leaves and FoliuMed allows for the exportation of pharmaceutical grade cannabis bulk extracts from Colombia to Germany.
  • With access to three of Clever Leaves pharmaceutical grade bulk cannabis extracts, Fidelio will be ramping up production using Clever Leaves full spectrum THC crude extract, standardized 20% CBD extract, and CBD isolate.
  • Were grateful for the opportunity to expand our international presence by partnering with FoliuMed and Fidelio, bringing Clever Leaves standard of production to a global scale.
  • FoliuMed is an international cannabis company with EU-GMP manufacturing operations (highest European production standard of Good Manufacturing Practise) in Germany.

IQVIA CFO to Speak at Barclays Global Healthcare Conference on March 16, 2022

Retrieved on: 
Thursday, March 3, 2022
Software, Research, Other Health, Networks, Pharmaceutical, Data Management, Technology, Medical Devices, Security, Science, Biotechnology, Health, Other Science, Technology, Privacy, Conference, Patient, Government, IQV, Industry, NYSE, Diversified Specialty Institute Holdings, Inc., Webcast, IQVIA

IQVIA Holdings Inc. (IQVIA) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Barclays Global Healthcare Conference in Miami, FL on Wednesday, March 16, 2022 at 1:35 p.m.

Key Points: 
  • IQVIA Holdings Inc. (IQVIA) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Barclays Global Healthcare Conference in Miami, FL on Wednesday, March 16, 2022 at 1:35 p.m.
  • A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com .
  • IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry.
  • IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise.

Establishment Labs to Present at the Cowen 42nd Annual Health Care Conference

Retrieved on: 
Wednesday, March 2, 2022
Surgery, Health, Medical Devices, Motiva, Conference, 21 CFR 820, Diversified Specialty Institute Holdings, Inc., MDSAP, FDA, ESTA, IDE, Clinical trial, Webcast, NASDAQ, Pharmaceutical industry

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving womens health and wellness, principally in breast aesthetics and reconstruction, today announced that Juan Jos Chacn-Quirs, Founder and Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, will present virtually at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022 at 2:10 pm Eastern Time.

Key Points: 
  • Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving womens health and wellness, principally in breast aesthetics and reconstruction, today announced that Juan Jos Chacn-Quirs, Founder and Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, will present virtually at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022 at 2:10 pm Eastern Time.
  • A live webcast of the presentation will be available on the Establishment Labs investor relations website at https://investors.establishmentlabs.com/ .
  • An archived version of the webcast will be available on the same website following completion of the event.
  • Establishment Labs Holdings Inc. is a global medical technology company dedicated to improving womens health and wellness.

The Australian Natural Therapeutics Group Signs a US$7.8M Product Agreement With Clever Leaves to Accelerate Medical Cannabis Access in Australia

Retrieved on: 
Monday, February 28, 2022
GLOBE, Therapeutic Goods Administration, Depression, GMP, BOCA, PTSD, Pain management, Good, Regulation of therapeutic goods, CBD, Diversified Specialty Institute Holdings, Inc., Twitter, Growth, Inflammation, Dementia, API, NASDAQ, Sleep apnea, Industry, Heart, LinkedIn, THC, Good agricultural practice, Nature, Anxiety, Cancer, GACP, Patient, Collecting practices of the Al-Thani Family, CEO, Research, Seizure, Leaf, Drug, Pharmaceutical industry, Facebook

This marks the largest supply agreement Clever Leaves has signed with an Australian cannabis company, assisting the companys growth as an emerging global leader in medical cannabis supply.

Key Points: 
  • This marks the largest supply agreement Clever Leaves has signed with an Australian cannabis company, assisting the companys growth as an emerging global leader in medical cannabis supply.
  • The Australian medical cannabis market is rapidly expanding and is expected to grow to US $1.2 billion by 2027, the 5th largest in the world.
  • Australia is a rapidly expanding market, and increasing product shipments to the country allows Clever Leaves to accelerate market growth further, said Andrs Fajardo, President and incoming CEO of Clever Leaves.
  • Both Clever Leaves and ANTG are devoting considerable efforts to ensure all clinically approved Australians can access high-quality, certified and affordable medicinal cannabis products.

Arcturus Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Update and Pipeline Progress

Retrieved on: 
Monday, February 28, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Clinical Trials, NHP, RNA transfection, ARCT, Omicron, File, Diversified Specialty Institute Holdings, Inc., Ornithine transcarbamylase deficiency, RNA, Research, Therapy, Infection, Safety, Cystic fibrosis, OTC, CMC, Review, Vaccine, Severe acute respiratory syndrome coronavirus 2, Biotechnology, EUA, Liver, Nasdaq, Arcturus Therapeutics, Patient, CTA, CEO, Vaccination, Pharmaceutical industry, Animal, Arcturus, Health

LUNAR-COV19; ARCT-154: Arcturus collaborator Vinbiocare has completed filing of an application for EUA with the Vietnam Ministry of Health.

Key Points: 
  • LUNAR-COV19; ARCT-154: Arcturus collaborator Vinbiocare has completed filing of an application for EUA with the Vietnam Ministry of Health.
  • In January 2022, Arcturus announced data from Phase 1/2 clinical development programs for ARCT-154 and ARCT-165 used as boosters following primary vaccination with Comirnaty.
  • Total revenue for the year ended December 31, 2021 was $12.4 million compared with $9.5 million for the year ended December 31, 2020.
  • Based on the current pipeline, the Companys cash position is expected to be sufficient to support operations into late 2023.

Clever Leaves Holdings Begins Sales of Cannabis Extracts in Germany Through Ethypharm Partnership

Retrieved on: 
Thursday, February 17, 2022
NASDAQ, CNS, Patient, EMEA, Certification, GACP, Diversified Specialty Institute Holdings, Inc., Central nervous system, GMP, Environment, BOCA, Pharmacist, WHO, LinkedIn, Pharmacy, CBD, GAP, Commercial Operating System (COS), Fair Debt Collection Practices Act, Marketing, Leaf, Growth, Research, Investment, GLOBE, THC, Pharmaceutical industry, EU

Partnering with an established pharmaceutical company like Ethypharm allows Clever Leaves Holdings to enter the German pharmaceutical market more broadly, which may accelerate the Companys expansion into the gradually expanding European cannabis market.

Key Points: 
  • Partnering with an established pharmaceutical company like Ethypharm allows Clever Leaves Holdings to enter the German pharmaceutical market more broadly, which may accelerate the Companys expansion into the gradually expanding European cannabis market.
  • This is especially relevant in an environment of constantly changing cannabis legislation across different countries, explained Andrs Fajardo, President of Clever Leaves Holdings.
  • "Partnership with Clever Leaves Holdings expands the range of products we offer to German patients and prescribers to treat Central Nervous System (CNS) diseases.
  • We look forward to the next launches planned with Clever Leaves Holdings in the months to come to further enlarge this offering."

Arcturus Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022

Retrieved on: 
Wednesday, February 16, 2022
Other Health, Health, Science, Other Science, Research, Cystic fibrosis, CureVac, Cystic Fibrosis Foundation, GSD, RNA, Diversified Specialty Institute Holdings, Inc., MicroRNA, Vaccine, Duke–NUS Medical School, RNA transfection, Glycogen storage disease type III, ARCT, Nasdaq, Fatty liver disease, OTC, III, Gene editing, Therapy, NASH, LinkedIn, Janssen Pharmaceuticals, Twitter, Takeda Pharmaceutical Company, Messenger RNA, Patent, Hepatitis B virus, DNA, Johnson & Johnson, Severe acute respiratory syndrome coronavirus 2, COVID-19, HBV, Baking

Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.

Key Points: 
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (with patents and patent applications issued in the U.S., Europe, Japan, China and other countries).
  • In addition, please connect with us on Twitter and LinkedIn .
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20220216005442/en/